Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis

Vanderhelst, Eef; Meırleır, Linda De; Verbanck, Sylvia; Piérard, Denis; Vincken, Walter; Malfroot, Anne

doi:10.1016/j.jcf.2011.08.006

Cited by 59 publications

(64 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2009 the prevalence of any S. aureus isolate from the respiratory tract of CF patients in USA was 65.8%, of which 23.7% were MRSA [19,20]. A recently published Belgian study reported 67% of their patient population as chronically infected with S. aureus and 18% harboring MRSA strains [21]. This is in contrast to findings in our patient population with only 0.3% of patients harboring MRSA strains and none with chronic MRSA infection.…”

Section: Discussioncontrasting

confidence: 72%

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF

Dalbøge

Pressler

Høiby

et al. 2013

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 72%

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF

Dalbøge

Pressler

Høiby

et al. 2013

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…Recent data suggest that MRSA strains are markers of more severe disease in CF patients but are not more virulent than MSSA strains . Acquisition of MRSA has been associated with hospitalization, the F508del genotype and the presence of bronchiectasis [116]. For treatment of S. aureus, recommended drugs, doses and regimens are given in Table 2.…”

Section: S Aureusmentioning

confidence: 99%

Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Döring

Flume

Heijerman³

et al. 2012

Journal of Cystic Fibrosis

427

453

View full text Add to dashboard Cite

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

show abstract

“…22 Similar findings have been reported by others. [224][225][226] In addition, MRSA has also been associated with increased mortality; in a cohort study of 19,833 individuals reported to the CFFPR with at least 2 years of follow-up, those with MRSA had a 1.27 higher risk of death when adjusted for severity of disease. 23…”

Section: Iiia3 Other Gram-negative Bacteriamentioning

confidence: 99%

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

346

382

View full text Add to dashboard Cite

The 2013 Infection Prevention and Control (IP&C) Guideline for Cystic Fibrosis (CF) was commissioned by the CF Foundation as an update of the 2003 Infection Control Guideline for CF. During the past decade, new knowledge and new challenges provided the following rationale to develop updated IP&C strategies for this unique population:1. The need to integrate relevant recommendations from evidence-based guidelines published since 2003 into IP&C practices for CF. These included guidelines from the Centers for Disease Control and Prevention (CDC)/Healthcare Infection Control Practices Advisory Committee (HICPAC), the World Health Organization (WHO), and key professional societies, including the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). During the past decade, new evidence has led to a renewed emphasis on source containment of potential pathogens and the role played by the contaminated healthcare environment in the transmission of infectious agents. Furthermore, an increased understanding of the importance of the application of implementation science, monitoring adherence, and feedback principles has been shown to increase the effectiveness of IP&C guideline recommendations.2. Experience with emerging pathogens in the non-CF population has expanded our understanding of droplet transmission of respiratory pathogens and can inform IP&C strategies for CF. These pathogens include severe acute respiratory syndrome coronavirus and the 2009 influenza A H1N1. Lessons learned about preventing transmission of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative pathogens in non-CF patient populations also can inform IP&C strategies for CF.

show abstract

Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis

Cited by 59 publications

References 19 publications

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF

Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Contact Info

Product

Resources

About